A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT02521870 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

241

Enrollment

INDUSTRY

Sponsor class

Stopped A strategic restructuring including the planned conclusion of clinical oncology development programs and no further sponsoring of the development of SD-101.

Conditions

Metastatic Melanoma
Head Neck Cancer

Interventions

DRUG: SD-101(1)
BIOLOGICAL: Pembrolizumab
DRUG: SD-101(2)
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: SD-101(3)
BIOLOGICAL: Pembrolizumab

Sponsor

Dynavax Technologies Corporation

Collaborators

[object Object]